To read the full story, subscribe or sign in.

Universal picture’s clearer in human RAS inhibition as phase I data from Immuneering screened at AACR

April 18, 2023

Immuneering Corp.’s positive pharmacokinetic, pharmacodynamic and safety phase I data with universal RAS inhibitor IMM-1-104 let the company move up the timeline for a recommended phase II dose from previous guidance of mid-2024 to early next year.

BioWorld Clinical Conferences American Association for Cancer Research Cancer

Today's news in brief

BioWorld

BioWorld briefs for Jan 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 22, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...